Cure8 research brief
New or unusual skin lesions in people with Crohn’s disease can signal immune‑related skin disease that may be linked to the underlying IBD, biologic therapy, or recent infections. Recognizing PNGD can prompt appropriate biopsy and management.
Adult patients with IBD (especially those on anti‑TNF therapy), clinicians (gastroenterologists, dermatologists), and caregivers monitoring skin changes in people on biologics.
A 52‑year‑old man with Crohn’s disease on infliximab developed asymptomatic erythematous papules after a recent shingles infection and temporary stoppage of infliximab. Skin biopsy showed changes diagnostic of PNGD. Topical corticosteroids led to complete resolution within one month, and infliximab was restarted without recurrence during >1 year follow‑up.
This report emphasizes that PNGD is multifactorial — IBD itself, anti‑TNF therapy, and post‑herpes zoster immune changes were considered possible contributing triggers. Management focused on treating the skin inflammation (topical steroid) and addressing associated conditions; the biologic was resumed successfully in this patient.
Single case report level evidence; useful for awareness but not for estimating frequency or risk. The source is an abstract/full text of a published case report in a dermatology journal.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This case suggests ustekinumab — a commonly used biologic for Crohn’s disease — might rarely be associated with kidney injury (FSGS). Patients and clinicians should be aware of new or worsening edema, proteinuria, or...
A single‑patient report suggests guselkumab (IL‑23 inhibitor) may control both refractory pyoderma gangrenosum and coexisting Crohn disease when several prior treatments failed.
Because it describes a severe new Crohn’s disease case temporally linked to COVID‑19, patients and clinicians should be aware that persistent or worsening GI symptoms after SARS‑CoV‑2 infection may merit investigation;...
